Webcast - Molecular Therapeutics in Non-Small Cell Lung Cancer
This enduring activity features recorded lectures from our live virtual activity - ‘Molecular Therapeutics in Non-Small Cell Lung Cancer: A Virtual International Conference’ held on 2/28/2021.
If you missed our live activity on 2/28/2021 or you attended the activity but would like to review the talks again, please sign up for this course and review the lectures and discussions. You may be eligible to claim CME/CE credits and MOC points if you did not participate in the associated live educational activity held on 2/28/2021. However, if you participated in the live activity, you must complete the required course objects for that activity (including a course evaluation) and claim credits for the live activity.
Review the program agenda for more details.
Registration is free for healthcare providers who are NOT employees of ACCME defined ineligible companies. Please proceed to registration and select "non-industry learner" if you are a healthcare provider involved in patient care and are not an employee of an ineligible company. Your fee will reset to $0.00.
If you are an employee of an ineligible company, please select "industry representative" and pay the industry registration fee when registering for this course. (An ineligible company is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients with the exception of hospitals and facilities that provide direct care to patients).
If you are an industry representative who paid for the live meeting, you can sign up for this activity without paying a fee. Please contact email@example.com for details.
This activity is directed toward medical oncologists who treat patients with lung cancer. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of lung cancer are also invited to participate.
Upon successful completion of this educational activity, participants will be able to:
- Discuss the nuances of the use of plasma- vs tissue-based molecular diagnostic testing
- Review recent data on the use of molecular targeted therapy in the adjuvant setting
- Summarize emerging data on the use of newly-available driver mutation testing and the targeted therapies available
- Explore the newest data on the therapeutic uses of checkpoint inhibitor therapy.
20-minute Recording: Advances in the detection of molecular driver mutations in lung adenocarcinoma, tissue vs plasma detection methods - Dr. Sandip Patel
30-minute Recording: EGFR-targeted therapy in the adjuvant treatment of lung adenocarcinoma - Dr. Narjust Duma
30-minute Recording: Emerging targets for molecular therapy – an expanding array of targetable driver mutations in advanced lung adenocarcinoma - Dr. Tejas Patil
45-minute Recording: Recent advances in the use of checkpoint inhibitors in the management of lung adenocarcinoma - Dr. Christina Baik
20-minute Recording: Dr. Baik and Dr. Patil discuss and answer questions related to their presentations
NARJUST DUMA, MD
Assistant Professor of Medicine
University of Wisconsin, Madison, WI
JOSEPH ROSALES, MD
Virginia Mason Medical Center, Seattle, WA
CHRISTINA BAIK, MD
Associate Professor of Medicine
University of Washington, Seattle, WA
TEJAS PATIL, MD
Assistant Professor of Medicine
University of Colorado, Aurora, CO
SANDIP PATEL, MD
Associate Professor of Medicine
University of California, San Diego, CA
No Members of this activity's planning committee or faculty have any relevant financial relationship with an ineligible entity with the exception of the following faculties:
- Dr. Narjust Duma: Dr. Duma has served as consultant for the following ineligible companies: Pfizer, AstraZeneca, Jansen and Neogenomics/inivata.
- Dr. Christina Baik: Dr. Baik has received research support from Celgene. In addition, research funding was provided by the following ineligible companies to the University of Washington, and not directly to Dr. Baik: BMS, Merck and Genentech.
- Dr. Sandip Patel: Dr. Patel has received research support and served as a consultant for the following ineligible companies: BMS, Merck, Roche/Genentech, AstraZeneca/MedImmune and Pfizer
All relevant financial relationships of individuals in control of the content have been identified and mitigated.
If any part of this activity will include the discussion of unapproved or investigational products, faculty discussing those products will clearly identify the product as investigational or not approved.
COMMERCIAL SUPPORT DISCLOSURE:
This activity has been supported with an independent medical education grant from AstraZeneca, Inc.
The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.
The Binaytara Foundation designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 2.0 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
NURSING CONTACT HOURS
Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.5 Contact Hours.
ABSM MAINTENANCE OF CERTIFICATE RECOGNITION STATEMENT:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 2.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 2.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.
This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0.
Healthcare providers ($0.00)
Industry employees ($200 + 3% Credit card fee)
You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.
This activity is free for all healthcare providers who are not employees of an ineligible entity.
No refunds will be issued if you have signed up for the activity but are not able to complete.